Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 14/20 | 0.39 |
| ▸ | CTSS | P25774 | 6/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7690020 | 0.91 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL7765475 | 0.91 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL701700 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL4371611 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL6722519 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL6719127 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL6722516 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL27429586 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL28160693 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL17232237 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517855-B2 | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof | ATTENUON, LLC (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1594521-A4 | PEPTIDES WHICH INHIBIT ANGIOGENESIS, CELL MIGRATION, CELL INVASION AND CELL PROLIFERATION, COMPOSITIONS AND USES THEREOF | ATTENUON LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1594521-A2 | PEPTIDES WHICH INHIBIT ANGIOGENESIS, CELL MIGRATION, CELL INVASION AND CELL PROLIFERATION, COMPOSITIONS AND USES THEREOF | Attenuon, LLC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040162239-A1 | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof | ATTENUON LLC | 2004-08-19 | — | — | US | disclosed |
| WO-2004047771-A2 | PEPTIDES WHICH INHIBIT ANGIOGENESIS, CELL MIGRATION, CELL INVASION AND CELL PROLIFERATION, COMPOSITIONS AND USES THEREOF | ATTENUON, LLC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162239-A1 | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof | HDGF, VIP, PGF | SMN1; SMN2 4508/4885CYP1A2 4839/4885CYP2C9 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.